Efficacy Falls Short: argenx to Terminate Phase 3 Trial of efgartigimod in Sjögren’s Disease
The UNITY trial, designed to determine whether treatment could reduce systemic disease activity, is to be stopped following an interim analysis. No new safety signals were identified, but full data are still needed to clarify why this treatment approach fell short.